Skip to main content

Addition to Moberg Pharma´s management team

STOCKHOLM, September 22nd 2017, Moberg Pharma AB (OMX: MOB) appoints Torbjörn Wärnheim, Director Pharmaceutical Innovation and Development, as a member of Moberg’s Management Team, effective from today. Torbjörn Wärnheim has had this position at Moberg Pharma since 2013.

Prior to his position with Moberg, Torbjörn Wärnheim was Vice President R&D at Fresenius Kabi. In addition to this he has held senior level positions at ACO HUD and Pharmacia & Upjohn among others. Torbjörn Wärnheim has a broad experience of pharmaceutical development of Rx- and OTC-products, and is associate professor at Royal Institute of Technology (KTH), Stockholm, with a research background within surface chemistry and physical chemistry of lipids.

“It is a pleasure to welcome Torbjörn Wärnheim to the Management Team at Moberg. I look forward to keep working together to continue to progress our development programs,” says Peter Wolpert, CEO of Moberg Pharma AB.

About this information
This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 a.m. (CET) on September 22nd 2017.

For additional information, please contact:
Peter Wolpert, CEO, telephone: +46 70 735 71 35, e-mail:
Anna Ljung, CFO, telephone: +46 707 66 60 30, e-mail:

About Moberg Pharma,
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, New Skin®, Dermoplast® and Domeboro®. Kerasal Nail® (Emtrix®, Zanmira® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).